Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies
We recently published a list of 10 Small Cap Stocks with High Potential. In this article, we are going to take a look at ...
Perspective Therapeutics (CATX) Gets a Buy from Truist Financial
Truist Financial analyst Nicole Germino assigned a Buy rating to the stock today. The company’s shares closed yesterday at $13.00.
bovnews3d
Perspective Therapeutics Inc (CATX) Stock Settles at $12.66: What’s Contributing to This Price Point?
Wedbush has recently initiated Perspective Therapeutics Inc (CATX) stock to Outperform rating, as announced on October 1, 2024, according to Finviz. Earlier, on September 25, 2024 ...
Buy Rating Affirmed for Perspective Therapeutics Amid Promising Early-Stage Drug Results for Melanoma Treatment
In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report), ...
Perspective falls after data for radiopharmaceutical in skin cancer
Perspective Therapeutics (CATX) stock drops 17% after mixed results from a Phase 1/2 trial for its radiopharmaceutical VMT01 ...
Investing4d
Truist sees overreaction to Perspective Therapeutics stock, calls it 'buying opportunity'
On Friday, Truist Securities maintained its Buy rating and $21.00 price target for Perspective Therapeutics Inc (NYSE:CATX) stock. The firm highlighted the recent investor concerns regarding ...
Investing3d
Perspective Therapeutics stock rises despite initial confusion over VMT01 melanoma study results
On Monday, Oppenheimer reaffirmed its Outperform rating on Perspective Therapeutics Inc (NYSE:CATX), maintaining a price target of $22.00. The affirmation follows an announcement made by the ...
Perspective Therapeutics Shares Fall After Melanoma Study Data Analysis
Shares of Perspective Therapeutics are down after results from a study of the company's treatment for melanoma showed lower doses were more effective, and higher-than-expected levels of radiation were ...
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Perspective Therapeutics is down 13% at last check Friday. The downtrend comes as drug study results are presented to medical ...
Insider Monkey5d
Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies
In this article, we are going to take a look at where Perspective Therapeutics, Inc. (NYSE:CATX) stands against other small cap stocks with high potential. As we transition from a tumultuous ...
Investing4d
Truist sees overreaction to Perspective Therapeutics stock, calls it 'buying opportunity'
On Friday, Truist Securities maintained its Buy rating and $21.00 price target for Perspective Therapeutics Inc (NYSE:CATX) stock. The firm highlighted the recent investor concerns regarding dosing ...
Investing3d
Perspective Therapeutics stock rises despite initial confusion over VMT01 melanoma study results
On Monday, Oppenheimer reaffirmed its Outperform rating on Perspective Therapeutics Inc (NYSE:CATX), maintaining a price target of $22.00. The affirmation follows an announcement made by the company ...